Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
doi: https://doi.org/10.1101/2022.03.03.22271827
Masaharu Shinkai
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takuhiro Sonoyama
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Akari Kamitani
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Risa Shibata
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Naomi Seki
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Shinya Omoto
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Masahiro Shinoda
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takashi Sato
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Naoki Ishii
4Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Kenji Igarashi
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Mari Ariyasu
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted March 06, 2022.
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Subject Area
Subject Areas
- Addiction Medicine (401)
- Allergy and Immunology (712)
- Anesthesia (204)
- Cardiovascular Medicine (2966)
- Dermatology (250)
- Emergency Medicine (444)
- Epidemiology (12789)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4613)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2940)
- Health Policy (1071)
- Hematology (393)
- HIV/AIDS (929)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (474)
- Neurology (4394)
- Nursing (237)
- Nutrition (646)
- Oncology (2286)
- Ophthalmology (651)
- Orthopedics (259)
- Otolaryngology (327)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (502)
- Public and Global Health (6986)
- Radiology and Imaging (1540)
- Respiratory Medicine (917)
- Rheumatology (443)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)